Project Grant R01CA300573
- Federal Grant Award Summary The National Cancer Institute awarded the University of Pittsburgh a $151,920 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This award supports fundamental research to develop and validate Nuclear Magnetic Resonance (NMR) strategies for investigating allosteric inhibitor binding effects on Src-family kinases implicated in acute myeloid leukemia (AML). The research aims to characterize...
- Federal Grant Award Summary The University of Pittsburgh received a $408,829 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2025, through May 31, 2027. This award supports the development of positive allosteric modulators (PAMs) targeting XCR1, a chemokine receptor expressed on conventional dendritic cells subtype 1 (CDC1s). The research will utilize DNA-encoded library (DEL) technology and cryo-electron...
- Federal Project Grant Award Summary The University of Pittsburgh received a $261,662 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded December 1, 2025, with completion targeted for April 16, 2029. This award supports an integrated in silico and in vivo genetic screening research initiative designed to identify subtype-specific hepatocellular carcinoma (HCC) genetic dependencies. The project addresses a significant clinical...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $657,776 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning August 1, 2025, and extending through May 31, 2030. This award supports the development of highly tumor-selective pan RAS inactivators to address oncogenic RAS-driven cancers, which account for approximately 46% of all human malignancies. The project addresses a significant clinical challenge: while...
- Federal Grant Award Summary The University of Pittsburgh has received a $121,857 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective August 1, 2025, through July 31, 2027. This award supports a K99/R00 Pathway to Independence research project investigating how anti-cancer drugs modulate T cell activity within the tumor microenvironment to overcome immune checkpoint blockade (ICB) resistance. The research delivers three integrated...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a Project Grant of $658,492 under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a novel targeted combinatorial therapy for advanced castration-resistant prostate cancer (ACRPC). The research, spanning from March 18, 2026 through February 28, 2031, focuses on optimizing the combination of CHK1 inhibitor SRA737 and WEE1 inhibitor AZD1775 to exploit the G2/M...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Pittsburgh a $141,566 Project Grant on March 24, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical research training and career development in cancer research. The grant funds research focused on understanding the conformational landscape and regulation of small GTPases (SMGs), specifically examining how oncogenic RhoA proteins function in cancer cell environments. The project...
- Federal Grant Award Summary The University of Pittsburgh received a $149,804 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded March 1, 2025, with completion scheduled for February 28, 2026. This award supports research investigating the impact of LAG3 (Lymphocyte Activation Gene 3) on CD8+ T cell motility and migration in the context of cancer immunotherapy. The research builds upon preliminary findings demonstrating that...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $151,040 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on December 12, 2025, with a completion date of November 30, 2027. This award supports biomedical research training and career development in cancer research aligned with the National Cancer Program's strategic priorities. The grant funds research investigating the relative and synergistic contributions of...
- Federal Grant Award Summary The University of Pittsburgh received a $169,982 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) awarded August 8, 2025, through July 31, 2030. The Program in Cancer Training and Education (PICTE) initiative provides comprehensive research training and professional development services for undergraduate students pursuing careers in cancer research. The award funds a 10-week intensive summer research program...
The University of Pittsburgh received a $435,788 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to develop active site-directed inhibitors and bifunctional degraders targeting mutant isocitrate dehydrogenase (IDH) enzymes. The award, effective April 1, 2026 through March 31, 2031, supports research addressing acquired drug resistance to FDA-approved IDH inhibitors (ivosidenib and enasidenib) in cancer patients with IDH mutations. The research will shift from allosteric modulators to active site-directed small molecule inhibitors and proteolysis targeting chimeras (PROTACs) designed to achieve proteasomal degradation of resistant IDH mutants in cancer cells. This project addresses a critical gap in cancer treatment by investigating how distinct biochemical features of IDH mutants contribute to specific tumor subtypes, particularly progressive gliomas and hematological malignancies. The deliverables include development of subtype-selective inhibitor compounds with novel chemotypes complementary to the stereoelectronic properties of individual IDH mutants, and evolution of these inhibitors into PROTAC therapeutics. These research outputs are intended to overcome therapeutic resistance mechanisms and provide novel treatment options for patients whose tumors have developed resistance to current targeted therapy approaches.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $435.8k | 4/1/26 |